3D·

NOVO NORDISK LAUNCHES NOVOCARE PHARMACY ON THE MARKET

$HIMS (+4,16 %)
$LLY (-5,26 %)
$NOVO B (-1,34 %)
$NVO (-1,59 %)

$NOVO B (-1,34 %) introduces NovoCare ® Pharmacy, which lowers the cost of all doses of FDA-approved Wegovy ® (semaglutide) to $499 per month and offers convenient home delivery for cash-paying patients.

While 90% of patients taking Wegovy ® have a co-pay of $0 to $25 per month, this offer was developed to support patients who are self-pay and do not have insurance coverage.

16 Comentarios

The W.@thewolfofallstreetz

A good example of the fear that prevails at Novo.

•

BamBamInvest@BamBamInvest

@thewolfofallstreetz yes, I agree

•

Soprano@Soprano

@thewolfofallstreetz Afraid of what?

••

Rot_ist_tot@Rot_ist_tot

@thewolfofallstreetz would interest me too?

•

Jan D.@Jan_Drosch

@thewolfofallstreetz Afraid of what?

••

The W.@thewolfofallstreetz

@Jan_Drosch Fear that Hims & Hers will take away attractive business in GLP-1s by offering a lower price point and personalizing the drugs.

•

Soprano@Soprano

@thewolfofallstreetz Apart from the fact that it wasn't true 9 hours ago, this answer has also aged extremely well

•

SemiGrowth@SemiGrowth

things must look pretty bleak in your portfolio at the moment...
What do you think about $ELF? What would have to happen for you to sell?
Growth should be significantly lower

•

BamBamInvest@BamBamInvest

@SemiGrowth well, I went from +20% at the beginning of the year to -5% YTD, but that can change quickly. At $ELF it's all just conjecture, China fears etc. There is no evidence for this and I don't believe that there will suddenly be no more growth. (I don't even want to go into the performance of the analysts and price targets here 😂) I have no intention of selling and if they deliver it will go up again quickly. I am relaxed because I am also convinced. Nothing has really changed compared to my investment . (10% more duties) I have often experienced such fluctuations and am used to volatility. My portfolio is otherwise still doing very well. ✌️

•

Mark777@Mark777

It will be interesting later this year when the Chinese Patent Office decides whether the generic drug will be approved by some pharmaceutical companies based there. The patent does not actually expire until 2026.
Allegedly, it will then be 25% cheaper over the thumb.

•

Aktienfox@Aktienfox

From 650$ to 500 Wow!

•

BamBamInvest@BamBamInvest

@Aktienfox immerhin 😁

•

ThemenmitKopf@topicswithhead

@BamBamInvest he is his shareholder. Expected emotionality. You too ik😂

•

BamBamInvest@BamBamInvest

@topicswithhead I'm already used to the cat and mouse game and you have to be used to Vola too 😂

•

Aktienfox@Aktienfox

@topicswithhead has nothing to do with it, only Hims is already influencing the markets and the new product from Novo is not sooo well priced...

•

ThemenmitKopf@topicswithhead

@Aktienfox Well, 150 is not a small amount and somehow they have to acquire the profits. From the point of view of others it is of course stupid, but in principle 500$ is very little. Obesity is one of the worst things that can happen to a person and is therefore probably worth several thousand euros per medication. If you look at it that way, it's very cheap. I also explained this to some extent in my Novo text. Almost every disease can also be triggered by obesity and the like.

••